Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received a consensus rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $19.43.

A number of brokerages have recently issued reports on REPL. HC Wainwright lifted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. lifted their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Finally, BMO Capital Markets increased their target price on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd.

Replimune Group Stock Up 4.7 %

NASDAQ REPL opened at $7.99 on Friday. The stock has a market cap of $615.35 million, a PE ratio of -2.60 and a beta of 1.26. The business has a 50 day moving average price of $10.85 and a two-hundred day moving average price of $11.78. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, sell-side analysts predict that Replimune Group will post -2.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds have recently added to or reduced their stakes in the business. Sterling Capital Management LLC raised its holdings in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after purchasing an additional 1,655 shares during the period. Graham Capital Management L.P. raised its stake in Replimune Group by 6.1% during the fourth quarter. Graham Capital Management L.P. now owns 30,180 shares of the company’s stock worth $365,000 after acquiring an additional 1,731 shares during the period. MetLife Investment Management LLC raised its stake in Replimune Group by 7.2% during the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company’s stock worth $456,000 after acquiring an additional 2,525 shares during the period. Algert Global LLC lifted its holdings in Replimune Group by 7.1% in the fourth quarter. Algert Global LLC now owns 45,820 shares of the company’s stock worth $555,000 after acquiring an additional 3,057 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Replimune Group by 24.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock valued at $198,000 after acquiring an additional 3,177 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.